Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Sonja Zweegman"'
Autor:
Hira Mian, Arleigh McCurdy, Smith Giri, Shakira Grant, Bram Rochwerg, Erica Winks, Ashley E. Rosko, Monika Engelhardt, Charlotte Pawlyn, Gordon Cook, Graham Jackson, Sara Bringhen, Thierry Facon, Alessandra Larocca, Sonja Zweegman, Tanya M. Wildes
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Multiple myeloma (MM) is an incurable blood cancer that primarily affects older adults. Several frailty tools have been developed to address the heterogeneity of aging in this population. Uptake of these measures has been variable, leading t
Externí odkaz:
https://doaj.org/article/076d33876b5743238d8aecfa4776d328
Autor:
Mirian Brink, Monique C. Minnema, Otto Visser, Mark-David Levin, Eduardus F. M. Ward Posthuma, Annemiek Broijl, Pieter Sonneveld, Marjolein van der Klift, Wilfried W. H. Roeloffzen, Matthijs Westerman, Cleo R. van Rooijen, Paul A. F. Geerts, Sonja Zweegman, Niels W. C. J. van de Donk, Avinash G. Dinmohamed
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 3, Pp 1-4 (2022)
Externí odkaz:
https://doaj.org/article/7eef70a1e844411ea966620a09685d92
Autor:
Mirian Brink, Kaz Groen, Pieter Sonneveld, Monique C. Minnema, Annemiek Broijl, Avinash G. Dinmohamed, Ellen van der Spek, Mark-David Levin, Paula F. Ypma, Esther de Waal, Eduardus F. M. Ward Posthuma, Sonja Zweegman, Niels W. C. J. van de Donk
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 11, Pp 1-7 (2021)
Abstract Identification of risk factors for early mortality (EM) in multiple myeloma (MM) patients may contribute to different therapeutic approaches in patients at risk for EM. This population-based study aimed to assess trends in EM and risk factor
Externí odkaz:
https://doaj.org/article/10e01658db454831b4b2e5e6af5592ee
Autor:
Mirian Brink, Otto Visser, Sonja Zweegman, Pieter Sonneveld, Annemiek Broyl, Niels W.C.J. van de Donk, Avinash G. Dinmohamed
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-4 (2021)
Externí odkaz:
https://doaj.org/article/fc8a243e6a9c43288b57b4718814d666
Autor:
Hilma J. van der Horst, A. Vera de Jonge, Ida H. Hiemstra, Anne T. Gelderloos, Daniella R. A. I. Berry, Nathalie J. Hijmering, Hendrik F. van Essen, Daphne de Jong, Martine E. D. Chamuleau, Sonja Zweegman, Esther C. W. Breij, Margaretha G. M. Roemer, Tuna Mutis
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
Abstract Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsie
Externí odkaz:
https://doaj.org/article/1763543d37b64f68b1819cf9d59358d5
Autor:
Evangelos Terpos, Joseph Mikhael, Roman Hajek, Ajai Chari, Sonja Zweegman, Hans C. Lee, María-Victoria Mateos, Alessandra Larocca, Karthik Ramasamy, Martin Kaiser, Gordon Cook, Katja C. Weisel, Caitlin L. Costello, Jennifer Elliott, Antonio Palumbo, Saad Z. Usmani
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-13 (2021)
Abstract Treatment options in multiple myeloma (MM) are increasing with the introduction of complex multi-novel-agent-based regimens investigated in randomized clinical trials. However, application in the real-world setting, including feasibility of
Externí odkaz:
https://doaj.org/article/2fce7cb5103c4985b99805727b7b90b8
Autor:
Mark-David Levin, Paula F. Ypma, Sonja Zweegman, Monique C. Minnema, Pieter Sonneveld, Esther G. M. de Waal, Eduardus F. M. Posthuma, Mirian Brink, Kaz Groen, Niels W.C.J. van de Donk, Ellen van der Spek, Avinash G Dinmohamed, Annemiek Broijl
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 11, Pp 1-7 (2021)
Blood Cancer Journal, 11(11):178. Nature Publishing Group
Blood Cancer Journal
Brink, M, Groen, K, Sonneveld, P, Minnema, M C, Broijl, A, Dinmohamed, A G, van der Spek, E, Levin, M D, Ypma, P F, de Waal, E, Posthuma, E F M W, Zweegman, S & van de Donk, N W C J 2021, ' Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands : a population-based study ', Blood cancer journal, vol. 11, no. 11, 178 . https://doi.org/10.1038/s41408-021-00571-8
Blood cancer journal, 11(11):178. Nature Publishing Group
Blood Cancer Journal, 11(11):178. Nature Publishing Group
Blood Cancer Journal
Brink, M, Groen, K, Sonneveld, P, Minnema, M C, Broijl, A, Dinmohamed, A G, van der Spek, E, Levin, M D, Ypma, P F, de Waal, E, Posthuma, E F M W, Zweegman, S & van de Donk, N W C J 2021, ' Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands : a population-based study ', Blood cancer journal, vol. 11, no. 11, 178 . https://doi.org/10.1038/s41408-021-00571-8
Blood cancer journal, 11(11):178. Nature Publishing Group
Identification of risk factors for early mortality (EM) in multiple myeloma (MM) patients may contribute to different therapeutic approaches in patients at risk for EM. This population-based study aimed to assess trends in EM and risk factors for EM
Autor:
Ida H. Hiemstra, Hilma J. van der Horst, Martine E.D. Chamuleau, A. Vera de Jonge, Margaretha G. M. Roemer, Tuna Mutis, Hendrik F. van Essen, Daniella R. A. I. Berry, Anne T. Gelderloos, Nathalie J. Hijmering, Sonja Zweegman, Daphne de Jong, Esther C.W. Breij
Publikováno v:
Blood Cancer Journal
Blood cancer journal, 11(2):38. Nature Publishing Group
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
van der Horst, H J, de Jonge, A V, Hiemstra, I H, Gelderloos, A T, Berry, D R A I, Hijmering, N J, van Essen, H F, de Jong, D, Chamuleau, M E D, Zweegman, S, Breij, E C W, Roemer, M G M & Mutis, T 2021, ' Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment ', Blood cancer journal, vol. 11, no. 2, 38 . https://doi.org/10.1038/s41408-021-00430-6
Blood cancer journal, 11(2):38. Nature Publishing Group
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
van der Horst, H J, de Jonge, A V, Hiemstra, I H, Gelderloos, A T, Berry, D R A I, Hijmering, N J, van Essen, H F, de Jong, D, Chamuleau, M E D, Zweegman, S, Breij, E C W, Roemer, M G M & Mutis, T 2021, ' Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment ', Blood cancer journal, vol. 11, no. 2, 38 . https://doi.org/10.1038/s41408-021-00430-6
Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from ne